Mark A. Velleca
2020 - G1 Therapeutics
In 2020, Mark A. Velleca earned a total compensation of $4M as Former Chief Executive Officer and President at G1 Therapeutics, which was about the same as previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $305,000 |
|---|---|
| Option Awards | $3,069,704 |
| Salary | $608,308 |
| Other | $8,550 |
| Total | $3,991,562 |
Velleca received $3.1M in option awards, accounting for 77% of the total pay in 2020.
Velleca also received $305K in non-equity incentive plan, $608.3K in salary and $8.6K in other compensation.
Rankings
In 2020, Mark A. Velleca's compensation ranked 2,858th out of 13,090 executives tracked by ExecPay. In other words, Velleca earned more than 78.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,858 out of 13,090 | 78th |
Division Manufacturing | 1,101 out of 5,624 | 80th |
Major group Chemicals And Allied Products | 406 out of 2,257 | 82nd |
Industry group Drugs | 350 out of 1,957 | 82nd |
Industry Pharmaceutical Preparations | 256 out of 1,462 | 83rd |
Source: SEC filing on April 28, 2021.
Velleca's colleagues
We found five more compensation records of executives who worked with Mark A. Velleca at G1 Therapeutics in 2020.
News
Black Diamond Therapeutics CEO Mark Velleca receives $2.9M in 2023
April 24, 2024
G1 Therapeutics CEO Mark Velleca's 2020 pay stays at $4M
April 28, 2021
G1 Therapeutics Chief Business Officer Mark Avagliano receives $5.5M in 2019
April 24, 2020
G1 Therapeutics Chief Commercial Officer John Demaree receives $7.5M in 2018
April 30, 2019